INT105393

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.70
First Reported 2000
Last Reported 2011
Negated 0
Speculated 2
Reported most in Body
Documents 66
Total Number 68
Disease Relevance 45.45
Pain Relevance 4.90

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (VEGFA) growth (VEGFA) extracellular region (VEGFA)
proteinaceous extracellular matrix (VEGFA) cytoplasm (VEGFA)
Anatomy Link Frequency
macrophages 6
brain 4
blood 4
osteoblasts 4
endothelial cells 4
VEGFA (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 405 100.00 Very High Very High Very High
chemokine 123 100.00 Very High Very High Very High
bDMF 10 100.00 Very High Very High Very High
ischemia 59 99.98 Very High Very High Very High
cytokine 382 99.88 Very High Very High Very High
Spinal cord 21 99.66 Very High Very High Very High
Migraine 2 98.36 Very High Very High Very High
COX-2 inhibitor 57 98.16 Very High Very High Very High
agonist 88 96.56 Very High Very High Very High
Inflammatory response 56 95.96 Very High Very High Very High
Disease Link Frequency Relevance Heat
INFLAMMATION 468 100.00 Very High Very High Very High
Pancreatic Cancer 26 100.00 Very High Very High Very High
Retina Disease 13 99.98 Very High Very High Very High
Lymphatic System Cancer 177 99.96 Very High Very High Very High
Pre-eclampsia 288 99.92 Very High Very High Very High
Cancer 2105 99.86 Very High Very High Very High
Colon Cancer 205 99.84 Very High Very High Very High
Ovarian Cancer 16 99.84 Very High Very High Very High
Advanced Or Metastatic Breast Cancer 66 99.80 Very High Very High Very High
Chronic Lymphoid Leukemia 8 99.76 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
RESULTS: Capsaicin treatment resulted in enhanced VEGF protein secretion in malignant melanoma cells independent of IL-1beta and TNF-alpha.
Positive_regulation (enhanced) of Localization (secretion) of VEGF protein
1) Confidence 0.70 Published 2002 Journal J. Cancer Res. Clin. Oncol. Section Body Doc Link 12242509 Disease Relevance 0.10 Pain Relevance 0
Although it failed to enhance endothelial tube formation in vitro [50], it increased VEGF secretion in cultured ARPE-19 cells [51].
Positive_regulation (increased) of Localization (secretion) of VEGF in tube
2) Confidence 0.57 Published 2009 Journal Molecular Vision Section Body Doc Link PMC2779062 Disease Relevance 0.95 Pain Relevance 0.09
The inhibitory effect of clonidine on the secretion of VEGF protein stimulated with IL-1beta was blocked by alpha(2)-ADR antagonists.
Positive_regulation (stimulated) of Localization (secretion) of VEGF protein
3) Confidence 0.50 Published 2009 Journal Graefes Arch. Clin. Exp. Ophthalmol. Section Body Doc Link 19011889 Disease Relevance 0 Pain Relevance 0
It has been shown that MM cells are capable of secreting VEGF in response to Interleukin-6 (IL-6) stimulation; in response to that VEGF stimulation microvascular endothelial cells and bone marrow stromal cells secrete in turn IL-6, a potent growth factor for malignant plasma cells, thus closing a paracrine loop [43].
Positive_regulation (response) of Localization (secrete) of VEGF in stromal cells associated with malignant neoplastic disease and multiple myeloma
4) Confidence 0.48 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2902424 Disease Relevance 1.49 Pain Relevance 0.04
relatively high concentrations, enhanced VEGF secretion from pancreatic cancer
Positive_regulation (enhanced) of Localization (secretion) of VEGF associated with pancreatic cancer
5) Confidence 0.48 Published 2008 Journal PPAR Research Section Body Doc Link PMC2366048 Disease Relevance 0.89 Pain Relevance 0.09
0), the steady-state plasma and interstitial free VEGF concentrations ([V]pl, [V]IS) were mapped out as functions of total VEGF-secretion rates from the normal tissue and calf compartments (qTotalVEGF,Normal and qTotalVEGF,Calf), where the individual isoforms VEGF121 and VEGF165 were secreted at a ratio of 1?
Positive_regulation (isoforms) of Localization (secreted) of VEGF121 in plasma
6) Confidence 0.48 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
VEGF is a potent angiogenic factor that acts as a modulator of vascular growth, remodeling, and permeability in the endometrium, decidua, and trophoblast, as well as during vascular development in the embryo, all of which are crucial processes related to normal implantation and placentation.37 VEGF expression and secretion can be induced by cytokines, growth factors, hormones, and local conditions such as hypoxia.37,38 Cellular VEGF production has been shown to increase under hypoxic conditions.
Positive_regulation (induced) of in embryo Localization (secretion) of VEGF in decidua associated with hypoxia and cytokine
7) Confidence 0.45 Published 2008 Journal Clinics Section Body Doc Link PMC2664731 Disease Relevance 0.62 Pain Relevance 0.05
Key messages

• During the early stage of ALI induced by IIR, the expression of VEGF and its receptors changes in the lung tissue. • Increased release of VEGF (found in BLF) may contribute to pulmonary permeability. • Reduced VEGF and its type I receptor in the lung tissue may affect lung epithelial cell survival.


Positive_regulation (Increased) of Localization (release) of VEGF associated with adult respiratory distress syndrome
8) Confidence 0.45 Published 2006 Journal Crit Care Section Body Doc Link PMC1751039 Disease Relevance 1.24 Pain Relevance 0.07
Abundant VEGF and MMP12 were secreted from both tumoural and non-tumoural cells, and these cytokines promote macrophage migration and angiogenesis.
Positive_regulation (Abundant) of Localization (secreted) of VEGF in macrophage associated with cytokine
9) Confidence 0.44 Published 2010 Journal Diagn Pathol Section Body Doc Link PMC2936386 Disease Relevance 0.71 Pain Relevance 0.14
The major classes of antiangiogenic therapy include (1) direct anti-VEGF acting molecules (anti-VEGF antibodies, VEGF-antisense nucleotides), (2) immunomodulatory drugs (IMIDs) with antiangiogenic properties, (3) receptor tyrosine kinase inhibitors that target VEGFR signaling as well as receptors of other (proangiogenic) factors, (4) the antiendothelial approach of metronomic therapy, and (5) other new compounds targeting signaling downstream to proangiogenic growth factors, such as mammalian target of rapamycin (mTOR) inhibitors, histone deacetylases' (HDAC) inhibitors, and proteasome inhibitors.
Positive_regulation (direct) of Localization (targeting) of anti-VEGF
10) Confidence 0.43 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2875768 Disease Relevance 1.03 Pain Relevance 0
CONCLUSIONS: There is increased VEGF and immature vascularization in patients with BPS/IC, and VEGF expression is associated with the degree of pain described by patients.
Positive_regulation (increased) of Localization (vascularization) of VEGF
11) Confidence 0.42 Published 2009 Journal BJU Int. Section Body Doc Link 19298410 Disease Relevance 0 Pain Relevance 0
The purpose of this study was to evaluate whether VEGF and angiogenesis can be observed in the degeneration of the LHB.
Positive_regulation (degeneration) of Localization (observed) of VEGF
12) Confidence 0.42 Published 2010 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2936349 Disease Relevance 0.22 Pain Relevance 0
In addition, rADM slightly up-regulated vascular endothelial growth factor secretion in 3/5 cell lines.
Positive_regulation (up-regulated) of Localization (secretion) of vascular endothelial growth factor
13) Confidence 0.40 Published 2007 Journal Int. J. Cancer Section Abstract Doc Link 17290391 Disease Relevance 1.62 Pain Relevance 0.23
Four factors were considered to increase the angiogenic potential of the PRP, including the concentrations of thrombin and calcium for platelet activation, the subsequent release of vascular endothelial growth factor (VEGF), production of platelet microparticles (PMPs), and inclusion of only peripheral blood mononuclear cells (PBMNCs) among white blood cells (WBCs).
Positive_regulation (increase) of Localization (release) of VEGF in blood
14) Confidence 0.40 Published 2010 Journal The Journal of Advanced Prosthodontics Section Body Doc Link PMC2984511 Disease Relevance 0.07 Pain Relevance 0
Four factors were considered to increase the angiogenic potential of the PRP, including the concentrations of thrombin and calcium for platelet activation, the subsequent release of vascular endothelial growth factor (VEGF), production of platelet microparticles (PMPs), and inclusion of only peripheral blood mononuclear cells (PBMNCs) among white blood cells (WBCs).
Positive_regulation (increase) of Localization (release) of vascular endothelial growth factor in blood
15) Confidence 0.40 Published 2010 Journal The Journal of Advanced Prosthodontics Section Body Doc Link PMC2984511 Disease Relevance 0.07 Pain Relevance 0
Activation with shear force, collagen, and low amount of calcium and thrombin (Group D) showed a significant increase in the release of VEGF (mean concentration 1264 pg/ml) as compared to the other methods using high calcium and thrombin (mean concentration 273 - 548 pg/ml), but the release of other growth factors were lowered (Fig. 1A).
Positive_regulation (increase) of Localization (release) of VEGF
16) Confidence 0.37 Published 2010 Journal The Journal of Advanced Prosthodontics Section Body Doc Link PMC2984511 Disease Relevance 0.06 Pain Relevance 0.04
Collagen and shear stimuli were intended to compensate for the decrease of other growth factors and increase the production of PMPs, but they also further increased the VEGF secretion.
Positive_regulation (increased) of Localization (secretion) of VEGF
17) Confidence 0.37 Published 2010 Journal The Journal of Advanced Prosthodontics Section Body Doc Link PMC2984511 Disease Relevance 0.09 Pain Relevance 0.05
In the present study, incorporation of other platelet activators, along with collagen and mechanical stimulus (shear force), increased the initial secretion of VEGF as compared to activation of 10 U/1 × 109 platelets with thrombin under 2 mM CaCl2 only (Data are not shown).
Positive_regulation (increased) of Localization (secretion) of VEGF in platelets
18) Confidence 0.37 Published 2010 Journal The Journal of Advanced Prosthodontics Section Body Doc Link PMC2984511 Disease Relevance 0.06 Pain Relevance 0.03
An excessive increase in the uPA system was shown to associate with tumour progression and metastasis formation [29-31], and an increase in MMPs is associated with degradation of ECM leading to the release of growth factors like bFGF and VEGF.
Positive_regulation (leading) of Localization (release) of VEGF associated with cancer and metastasis
19) Confidence 0.36 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2841144 Disease Relevance 1.05 Pain Relevance 0.04
Angiogenesis, or the formation of new blood vessels, is critical to tumor growth and is principally mediated via tumoral secretion of vascular endothelial growth factor (VEGF).
Positive_regulation (mediated) of Localization (secretion) of VEGF in blood vessels associated with cancer
20) Confidence 0.35 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2242654 Disease Relevance 0.44 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox